Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × Immune Checkpoint Inhibitors × Clear all

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04353479 2020-04-20

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute